Most Recent Events

27 Oct 2017
Planned End Date changed from 1 Oct 2019 to 18 Oct 2019.

27 Oct 2017
According to a Merck & Co media release, company has withdrawn its European application for KEYTRUDA (pembrolizumab) in combination with pemetrexed and carboplatin as a first-line treatment for metastatic nonsquamous non-small cell lung cancer (NSCLC).The application was based on findings from this trial.